The recently FDA-approved GENOSYL® inhaled nitric oxide may have pulmonary and antiviral benefits in … [Read More...]
VERO Biotech is an emerging biotechnology company focused on the design, development,
and commercialization of next generation inhaled Nitric Oxide (NO) delivery systems
to address unmet medical needs of patients with cardiopulmonary conditions.
At Vero Biotech, our mission is to improve the lives of patients by developing innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed customer expectations in terms of safety, efficacy, and value by focusing on the science, development, and commercialization of our innovations
"The reasonable man adapts himself to the world; the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man."~George Bernard Shaw
Inhaled Nitric Oxide Delivery
Inhaled Nitric Oxide (NO) has the potential to benefit patients, from neonates to adults
with a range of cardiopulmonary conditions characterized by pulmonary hypertension – whether the
patients are in critical care hospital settings, chronic care facilities, or even in the home.
We are developing GENOSYL® delivery systems to meet the needs of patients
and critical care providers wherever inhaled NO is part of a treatment option.